Medicare AdvantagePrior AuthMedium impact
MA08.177a, Imetelstat (Rytelo®)
Independence Blue Cross·Pharmacy, Hematology, Oncology·Pharmacy
Effective date
Jun 29, 2026
We identified it
Jun 30, 2026
Summary
Medicare Advantage policy MA08.177a establishes new medical necessity criteria for Imetelstat (Rytelo®), a pharmaceutical treatment. This pharmacy policy change requires billing and clinical teams to verify patient eligibility against updated medical necessity requirements before billing or dispensing this medication. Failure to comply may result in claim denials for Medicare Advantage beneficiaries.
Action Required
By June 29, 2026: Pharmacy and billing teams must obtain and review the complete MA08.177a policy text to identify specific medical necessity criteria for Imetelstat (Rytelo®). Update prior authorization workflows and pharmacy system rules to enforce these criteria before dispensing or billing claims. Train pharmacy staff and billing team on new requirements. Coordinate with providers to ensure prescriptions meet documented medical necessity standards. Implement claim screening to deny or hold claims that do not meet the new criteria.